## Mark A Geyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11859081/publications.pdf Version: 2024-02-01



MADK & CEVED

#	Article	IF	CITATIONS
1	The Effects of Cannabis Use on Cognitive Function in Healthy Aging: A Systematic Scoping Review. Archives of Clinical Neuropsychology, 2021, 36, 673-685.	0.3	10
2	The relationship between cannabis use and cognition in people with bipolar disorder: A systematic scoping review. Psychiatry Research, 2021, 297, 113695.	1.7	5
3	Computational identification of variables in neonatal vocalizations predictive for postpubertal social behaviors in a mouse model of 16p11.2 deletion. Molecular Psychiatry, 2021, 26, 6578-6588.	4.1	7
4	Chronic antipsychotic treatment exerts limited effects on the mania-like behavior of dopamine transporter knockdown mice. Behavioural Brain Research, 2021, 405, 113167.	1.2	1
5	HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (ΰ9-Tetrahydrocannabinol)-Induced Deficits. International Journal of Neuropsychopharmacology, 2021, 24, 894-906.	1.0	6
6	Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporterâ€deficient mice using the 5â€choice CPT. Bipolar Disorders, 2020, 22, 46-58.	1.1	21
7	Sustained attention and vigilance deficits associated with HIV and a history of methamphetamine dependence. Drug and Alcohol Dependence, 2020, 215, 108245.	1.6	9
8	Analysis of Genetically Regulated Gene Expression Identifies a Prefrontal PTSD Gene, SNRNP35, Specific to Military Cohorts. Cell Reports, 2020, 31, 107716.	2.9	44
9	Serotonin and schizophrenia. Handbook of Behavioral Neuroscience, 2020, 31, 711-743.	0.7	7
10	Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen. Psychopharmacology, 2019, 236, 821-830.	1.5	19
11	Dopamine transporter knockdown mice in the behavioral pattern monitor: A robust, reproducible model for mania-relevant behaviors. Pharmacology Biochemistry and Behavior, 2019, 178, 42-50.	1.3	15
12	Overview of the Biography and Legacy of Professor Athina Markou. Biological Psychiatry, 2018, 83, 910-912.	0.7	0
13	Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance UseÂDisorders. Biological Psychiatry, 2018, 83, 915-923.	0.7	16
14	Individual variation in working memory is associated with fear extinction performance. Behaviour Research and Therapy, 2018, 102, 52-59.	1.6	13
15	Amphetamine Modestly Improves Conners' Continuous Performance Test Performance in Healthy Adults. Journal of the International Neuropsychological Society, 2018, 24, 283-293.	1.2	26
16	COMT val158met polymorphism links to altered fear conditioning and extinction are modulated by PTSD and childhood trauma. Depression and Anxiety, 2018, 35, 32-42.	2.0	14
17	Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning. European Neuropsychopharmacology, 2018, 28, 1217-1231.	0.3	4
18	Amphetamine improves mouse and human attention in the 5-choice continuous performance test. Neuropharmacology, 2018, 138, 87-96.	2.0	37

#	Article	IF	CITATIONS
19	Effects of LPS-induced immune activation prior to trauma exposure on PTSD-like symptoms in mice. Behavioural Brain Research, 2017, 323, 117-123.	1.2	27
20	Striatal dopamine D1 receptor suppression impairs reward-associative learning. Behavioural Brain Research, 2017, 323, 100-110.	1.2	23
21	Genetic loci associated with heart rate variability and their effects on cardiac disease risk. Nature Communications, 2017, 8, 15805.	5.8	95
22	Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown—a model of mania. Psychopharmacology, 2017, 234, 1017-1028.	1.5	22
23	Modafinil improves attentional performance in healthy, non-sleep deprived humans at doses not inducing hyperarousal across species. Neuropharmacology, 2017, 125, 254-262.	2.0	17
24	Fear learning alterations after traumatic brain injury and their role in development of posttraumatic stress symptoms. Depression and Anxiety, 2017, 34, 723-733.	2.0	27
25	The COMT Val158Met Polymorphism and Exploratory Behavior in Bipolar Mania. Molecular Neuropsychiatry, 2017, 3, 151-156.	3.0	6
26	The effects of reduced dopamine transporter function and chronic lithium on motivation, probabilistic learning, and neurochemistry in mice: Modeling bipolar mania. Neuropharmacology, 2017, 113, 260-270.	2.0	28
27	PREPULSE INHIBITION DEFICITS ONLY IN FEMALES WITH OBSESSIVE-COMPULSIVE DISORDER. Depression and Anxiety, 2016, 33, 238-246.	2.0	20
28	Effect of Hallucinogens on Unconditioned Behavior. Current Topics in Behavioral Neurosciences, 2016, 36, 159-199.	0.8	63
29	Effect of 5-HT2A and 5-HT2C receptors on temporal discrimination by mice. Neuropharmacology, 2016, 107, 364-375.	2.0	34
30	Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. Journal of Psychopharmacology, 2016, 30, 1072-1081.	2.0	159
31	Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. Psychopharmacology, 2016, 233, 3513-3525.	1.5	45
32	Prepulse Inhibition Deficits in Obsessive-Compulsive Disorder are More Pronounced in Females. Neuropsychopharmacology, 2016, 41, 2963-2964.	2.8	16
33	Athina Markou. Neuropsychopharmacology, 2016, 41, 3121-3122.	2.8	1
34	HIGH AND LOW THRESHOLD FOR STARTLE REACTIVITY ASSOCIATED WITH PTSD SYMPTOMS BUT NOT PTSD RISK: EVIDENCE FROM A PROSPECTIVE STUDY OF ACTIVE DUTY MARINES. Depression and Anxiety, 2016, 33, 192-202.	2.0	15
35	Overexpression of Forebrain CRH During Early Life Increases Trauma Susceptibility in Adulthood. Neuropsychopharmacology, 2016, 41, 1681-1690.	2.8	33
36	Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology, 2016, 233, 225-233.	1.5	33

#	Article	IF	CITATIONS
37	Locomotor Profiling from Rodents to the Clinic and Back Again. Current Topics in Behavioral Neurosciences, 2015, 28, 287-303.	0.8	23
38	GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders. Neuropsychopharmacology, 2015, 40, 2715-2726.	2.8	33
39	Restoration of <i>Sp4</i> in Forebrain GABAergic Neurons Rescues Hypersensitivity to Ketamine in <i>Sp4</i> Hypomorphic Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyv063.	1.0	4
40	Cell type-specific modifications of corticotropin-releasing factor (CRF) and its type 1 receptor (CRF1) on startle behavior and sensorimotor gating. Psychoneuroendocrinology, 2015, 53, 16-28.	1.3	12
41	Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology, 2015, 232, 3455-3467.	1.5	29
42	Lysergic Acid Diethylamide and Psilocybin Revisited. Biological Psychiatry, 2015, 78, 516-518.	0.7	13
43	Investigating the underlying mechanisms of aberrant behaviors in bipolar disorder from patients to models. Neuroscience and Biobehavioral Reviews, 2015, 58, 4-18.	2.9	25
44	Association of Predeployment Heart Rate Variability With Risk of Postdeployment Posttraumatic Stress Disorder in Active-Duty Marines. JAMA Psychiatry, 2015, 72, 979.	6.0	117
45	Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology, 2015, 51, 459-471.	1.3	147
46	The catecholaminergic–cholinergic balance hypothesis of bipolar disorder revisited. European Journal of Pharmacology, 2015, 753, 114-126.	1.7	81
47	Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia Behavioral Neuroscience, 2014, 128, 460-467.	0.6	8
48	Inhibition of protein translation by the DISC1-Boymaw fusion gene from a Scottish family with major psychiatric disorders. Human Molecular Genetics, 2014, 23, 5683-5705.	1.4	31
49	Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behavioural Pharmacology, 2014, 25, 12-22.	0.8	31
50	Heart Rate Variability Characteristics in a Large Group of Active-Duty Marines and Relationship to Posttraumatic Stress. Psychosomatic Medicine, 2014, 76, 292-301.	1.3	80
51	Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology, 2014, 77, 200-207.	2.0	95
52	Isolation rearing effects on probabilistic learning and cognitive flexibility in rats. Cognitive, Affective and Behavioral Neuroscience, 2014, 14, 388-406.	1.0	66
53	Sleep deprivation impairs performance in the 5-choice continuous performance test: Similarities between humans and mice. Behavioural Brain Research, 2014, 261, 40-48.	1.2	49
54	Reduced Dopamine Transporter Functioning Induces High-Reward Risk-Preference Consistent with Bipolar Disorder. Neuropsychopharmacology, 2014, 39, 3112-3122.	2.8	78

#	Article	IF	CITATIONS
55	Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy â€~Low and High Gating' Humans and Relation to Psychometry. Neuropsychopharmacology, 2014, 39, 2485-2496.	2.8	10
56	Forebrain-Specific CRF Overproduction During Development is Sufficient to Induce Enduring Anxiety and Startle Abnormalities in Adult Mice. Neuropsychopharmacology, 2014, 39, 1409-1419.	2.8	28
57	Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. Journal of Affective Disorders, 2014, 155, 247-254.	2.0	41
58	Habituation. , 2014, , 1-4.		0
59	Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task. Psychopharmacology, 2013, 225, 661-674.	1.5	54
60	Characterization of the head-twitch response induced by hallucinogens in mice. Psychopharmacology, 2013, 227, 727-739.	1.5	139
61	The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice. Archives of Pharmacal Research, 2013, 36, 854-863.	2.7	10
62	Animal models and measures of perceptual processing in Schizophrenia. Neuroscience and Biobehavioral Reviews, 2013, 37, 2092-2098.	2.9	34
63	Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Research, 2013, 205, 117-126.	1.7	51
64	Role of the 5-HT2A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. Neuropharmacology, 2013, 70, 218-227.	2.0	42
65	Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochemical Pharmacology, 2013, 86, 1122-1132.	2.0	112
66	Inhibitory deficits in euthymic bipolar disorder patients assessed in the human behavioral pattern monitor. Journal of Affective Disorders, 2013, 150, 948-954.	2.0	31
67	Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behavioural Brain Research, 2013, 240, 119-133.	1.2	67
68	Neuropharmacology of Lysergic Acid Diethylamide (LSD) and Other Hallucinogens. , 2013, , 625-635.		3
69	Prepulse Inhibition in HIV-Associated Neurocognitive Disorders. Journal of the International Neuropsychological Society, 2013, 19, 709-717.	1.2	34
70	Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behavioural Brain Research, 2013, 236, 210-220.	1.2	27
71	Serotonergic hallucinogens as translational models relevant to schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2165-2180.	1.0	51
72	Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. International Journal of Neuropsychopharmacology, 2013, 16, 1021-1031.	1.0	45

#	Article	IF	CITATIONS
73	Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers. Neuropsychopharmacology, 2012, 37, 630-640.	2.8	168
74	From antipsychotic to anti-schizophrenia drugs: role of animal models. Trends in Pharmacological Sciences, 2012, 33, 515-521.	4.0	30
75	Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology, 2012, 62, 1381-1390.	2.0	32
76	The effect of pregabalin on sensorimotor gating in †low' gating humans and mice. Neuropharmacology, 2012, 63, 480-485.	2.0	16
77	Four factors underlying mouse behavior in an open field. Behavioural Brain Research, 2012, 233, 55-61.	1.2	77
78	Impaired Sensorimotor Gating in Unmedicated Adults with Obsessive–Compulsive Disorder. Neuropsychopharmacology, 2012, 37, 1216-1223.	2.8	166
79	Behavioral Animal Models to Assess Pro-cognitive Treatments for Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 39-79.	0.9	24
80	Perceptual Measurement in Schizophrenia: Promising Electrophysiology and Neuroimaging Paradigms From CNTRICS. Schizophrenia Bulletin, 2012, 38, 81-91.	2.3	59
81	Characterization of Neurophysiologic and Neurocognitive Biomarkers for Use in Genomic and Clinical Outcome Studies of Schizophrenia. PLoS ONE, 2012, 7, e39434.	1.1	159
82	Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nature Reviews Drug Discovery, 2012, 11, 141-168.	21.5	960
83	Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology, 2012, 221, 709-718.	1.5	33
84	Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. Pharmacology Biochemistry and Behavior, 2012, 102, 88-94.	1.3	4
85	Working memory span capacity improved by a D2 but not D1 receptor family agonist. Behavioural Brain Research, 2011, 219, 181-188.	1.2	27
86	The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behavioural Brain Research, 2011, 222, 183-192.	1.2	72
87	Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology, 2011, 25, 1548-1561.	2.0	135
88	Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 2011, 61, 364-381.	2.0	274
89	Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. Journal of Psychopharmacology, 2011, 25, 934-943.	2.0	95
90	Repeated Assessment of Exploration and Novelty Seeking in the Human Behavioral Pattern Monitor in Bipolar Disorder Patients and Healthy Individuals. PLoS ONE, 2011, 6, e24185.	1.1	44

#	Article	IF	CITATIONS
91	Predictive animal models of mania: hits, misses and future directions. British Journal of Pharmacology, 2011, 164, 1263-1284.	2.7	117
92	Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology, 2011, 215, 697-707.	1.5	31
93	Dopamine Receptor Mediation of the Exploratory/Hyperactivity Effects of Modafinil. Neuropsychopharmacology, 2011, 36, 1385-1396.	2.8	46
94	Genetic Models of Sensorimotor Gating: Relevance to Neuropsychiatric Disorders. Current Topics in Behavioral Neurosciences, 2011, 12, 251-318.	0.8	120
95	The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Journal of Psychopharmacology, 2011, 25, 1600-1613.	2.0	26
96	The Melanin-Concentrating Hormone (MCH) System Modulates Behaviors Associated with Psychiatric Disorders. PLoS ONE, 2011, 6, e19286.	1.1	20
97	The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice. Behavioural Pharmacology, 2010, 21, 135-143.	0.8	18
98	Age-associated improvements in cross-modal prepulse inhibition in mice Behavioral Neuroscience, 2010, 124, 133-140.	0.6	27
99	LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology, 2010, 208, 179-189.	1.5	62
100	GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology, 2010, 208, 443-454.	1.5	71
101	Heart rate variability in bipolar mania and schizophrenia. Journal of Psychiatric Research, 2010, 44, 168-176.	1.5	162
102	Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats. Neuropeptides, 2010, 44, 421-429.	0.9	7
103	The mania-like exploratory profile in genetic dopamine transporter mouse models is diminished in a familiar environment and reinstated by subthreshold psychostimulant administration. Pharmacology Biochemistry and Behavior, 2010, 96, 7-15.	1.3	56
104	The quantitative assessment of motor activity in mania and schizophrenia. Journal of Affective Disorders, 2010, 120, 200-206.	2.0	84
105	Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neuroscience and Biobehavioral Reviews, 2010, 34, 1296-1306.	2.9	58
106	Reduced NMDAR1 expression in the Sp4 hypomorphic mouse may contribute to endophenotypes of human psychiatric disorders. Human Molecular Genetics, 2010, 19, 3797-3805.	1.4	36
107	Studies in Genetically Modified Mice Suggest Novel Mechanisms of Mood Regulation. Biological Psychiatry, 2010, 68, 500-502.	0.7	4
108	Isolation rearing-induced deficits in contextual fear learning do not require CRF2 receptors. Behavioural Brain Research, 2010, 209, 80-84.	1.2	42

Mark A Geyer

#	Article	IF	CITATIONS
109	Quantifying over-activity in bipolar and schizophrenia patients in a human open field paradigm. Psychiatry Research, 2010, 178, 84-91.	1.7	69
110	Serotonin and Schizophrenia. Handbook of Behavioral Neuroscience, 2010, 21, 585-620.	0.7	15
111	Animal Models of Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 391-433.	0.8	75
112	5-HT2A and 5-HT2C Receptors Exert Opposing Effects on Locomotor Activity in Mice. Neuropsychopharmacology, 2009, 34, 1958-1967.	2.8	127
113	Perception Measurement in Clinical Trials of Schizophrenia: Promising Paradigms From CNTRICS. Schizophrenia Bulletin, 2009, 35, 163-181.	2.3	109
114	A Reverse-Translational Study of Dysfunctional Exploration in Psychiatric Disorders. Archives of General Psychiatry, 2009, 66, 1072.	13.8	174
115	Sept5 deficiency exerts pleiotropic influence on affective behaviors and cognitive functions in mice. Human Molecular Genetics, 2009, 18, 1652-1660.	1.4	78
116	Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, 122, 150-202.		285
117	Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology, 2009, 206, 699-714.	1.5	41
118	Prepulse inhibition and genetic mouse models of schizophrenia. Behavioural Brain Research, 2009, 204, 282-294.	1.2	184
119	Habituation and sensitization of acoustic startle: Opposite influences of dopamine D1 and D2-family receptors. Neurobiology of Learning and Memory, 2009, 92, 243-248.	1.0	36
120	Habituation revisited: An updated and revised description of the behavioral characteristics of habituation. Neurobiology of Learning and Memory, 2009, 92, 135-138.	1.0	1,167
121	Chronic Reductions in Serotonin Transporter Function Prevent 5-HT1B-Induced Behavioral Effects in Mice. Biological Psychiatry, 2009, 65, 401-408.	0.7	86
122	Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models. Neuropsychopharmacology, 2009, 34, 74-89.	2.8	301
123	The 5-Choice Continuous Performance Test: Evidence for a Translational Test of Vigilance for Mice. PLoS ONE, 2009, 4, e4227.	1.1	159
124	Transcription Factor SP4 Is a Susceptibility Gene for Bipolar Disorder. PLoS ONE, 2009, 4, e5196.	1.1	58
125	A Kappa Opioid Model of Atypical Altered Consciousness and Psychosis: U50488, DOI, AC90179 Effects on Prepulse Inhibition and Locomotion in Mice. Journal of Young Investigators, 2009, 19, 1-7.	0.0	11
126	Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotoxicity Research, 2008, 14, 71-78.	1.3	81

#	Article	IF	CITATIONS
127	Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. Psychopharmacology, 2008, 201, 55-66.	1.5	42
128	Inactivation of the 5-HT7 Receptor Partially Blocks Phencyclidine-Induced Disruption of Prepulse Inhibition. Biological Psychiatry, 2008, 63, 98-105.	0.7	50
129	Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences, 2008, 29, 445-453.	4.0	401
130	Developing New Drugs for Schizophrenia: From Animals to the Clinic. , 2008, , 199-261.		18
131	Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex, 2008, 44, 1206-1214.	1.1	65
132	Prepulse inhibition and "psychosis-proneness―in healthy individuals: An fMRI study. European Psychiatry, 2008, 23, 274-280.	0.1	61
133	Patients with Premenstrual Dysphoric Disorder have Increased Startle Response Across both Cycle Phases and Lower Levels of Prepulse Inhibition During the Late Luteal Phase of the Menstrual Cycle. Neuropsychopharmacology, 2008, 33, 2283-2290.	2.8	57
134	Spontaneous Nicotine Withdrawal Potentiates the Effects of Stress in Rats. Neuropsychopharmacology, 2008, 33, 2131-2138.	2.8	40
135	Haloperidol Differentially Modulates Prepulse Inhibition and P50 Suppression in Healthy Humans Stratified for Low and High Gating Levels. Neuropsychopharmacology, 2008, 33, 497-512.	2.8	97
136	Contributions of Dopamine D1, D2, and D3 Receptor Subtypes to the Disruptive Effects of Cocaine on Prepulse Inhibition in Mice. Neuropsychopharmacology, 2008, 33, 2648-2656.	2.8	55
137	Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behavioural Pharmacology, 2008, 19, 562-565.	0.8	53
138	Preclinical Approaches to Understanding Anxiety Disorders. , 2008, , .		0
139	Inhibición prepulso y "propensión a la psicosis―en individuos sanos: un estudio de RMf. European Psychiatry (Ed Española), 2008, 15, 339-346.	0.0	0
140	The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval. Neuropsychopharmacology, 2007, 32, 1876-1887.	2.8	142
141	A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. International Journal of Neuropsychopharmacology, 2007, 10, 463.	1.0	104
142	The indirect serotonergic agonist d-fenfluramine and prepulse inhibition in healthy men. Neuropharmacology, 2007, 52, 1088-1094.	2.0	9
143	Overview of Animal Models of Schizophrenia. Current Protocols in Neuroscience, 2007, 39, Unit 9.24.	2.6	25
144	Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating. Pharmacology Biochemistry and Behavior, 2007, 86, 550-558.	1.3	19

#	Article	IF	CITATIONS
145	A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor. Neuroscience and Biobehavioral Reviews, 2007, 31, 882-896.	2.9	104
146	A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia. Biological Psychiatry, 2006, 60, 253-264.	0.7	319
147	Isolation rearing of mice induces deficits in prepulse inhibition of the startle response. Behavioural Brain Research, 2006, 169, 162-167.	1.2	63
148	Prepulse inhibition and P50 suppression: Commonalities and dissociations. Psychiatry Research, 2006, 143, 147-158.	1.7	94
149	lloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology, 2006, 51, 457-465.	2.0	49
150	The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology, 2006, 189, 319-329.	1.5	73
151	The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps?. Neurotoxicity Research, 2006, 10, 211-220.	1.3	144
152	Convergence and Divergence in the Neurochemical Regulation of Prepulse Inhibition of Startle and N40 Suppression in Rats. Neuropsychopharmacology, 2006, 31, 506-515.	2.8	54
153	Differential Contributions of Dopamine D1, D2, and D3 Receptors to MDMA-Induced Effects on Locomotor Behavior Patterns in Mice. Neuropsychopharmacology, 2006, 31, 2349-2358.	2.8	108
154	Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 910-918.	1.3	176
155	Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?. Dialogues in Clinical Neuroscience, 2006, 8, 9-16.	1.8	62
156	Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not α2-adrenoceptors. Psychopharmacology, 2005, 180, 491-500.	1.5	24
157	An Investigation of the Efficacy of Mood Stabilizers in Rodent Models of Prepulse Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 1163-1171.	1.3	44
158	A Developmental Influence of the N-Methyl-D-Aspartate Receptor NR3A Subunit on Prepulse Inhibition of Startle. Biological Psychiatry, 2005, 57, 1147-1152.	0.7	26
159	Developing Predictive Animal Models and Establishing a Preclinical Trials Network for Assessing Treatment Effects on Cognition in Schizophrenia. Schizophrenia Bulletin, 2005, 31, 888-894.	2.3	87
160	Information-processing deficits and cognitive dysfunction in panic disorder. Journal of Psychiatry and Neuroscience, 2005, 30, 37-43.	1.4	89
161	The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice. Neuropsychopharmacology, 2004, 29, 221-228.	2.8	119
162	Attentional Modulation of Prepulse Inhibition: A New Startle Paradigm. Neuropsychobiology, 2004, 49, 88-93.	0.9	42

#	Article	IF	CITATIONS
163	Corticotropin-Releasing Factor Receptors CRF1 and CRF2 Exert Both Additive and Opposing Influences on Defensive Startle Behavior. Journal of Neuroscience, 2004, 24, 6545-6552.	1.7	122
164	Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis—A longitudinal study. European Archives of Psychiatry and Clinical Neuroscience, 2004, 254, 415-421.	1.8	85
165	Interactions of the mGluR5 gene with breeding and maternal factors on startle and prepulse inhibition in mice. Neurotoxicity Research, 2004, 6, 79-90.	1.3	42
166	Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. Psychopharmacology, 2004, 173, 418-424.	1.5	12
167	MDMA ?ecstasy? alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology, 2004, 173, 310-317.	1.5	43
168	Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology, 2004, 174, 1.	1.5	59
169	Reduced n-acetylaspartate in the temporal cortex of rats reared in isolation. Biological Psychiatry, 2004, 56, 296-299.	0.7	29
170	The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behavioural Brain Research, 2004, 152, 341-349.	1.2	57
171	Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Research, 2004, 126, 51-61.	1.7	109
172	Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology, 2003, 169, 240-246.	1.5	60
173	Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology, 2003, 170, 178-187.	1.5	103
174	Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Research - Neuroimaging, 2003, 122, 99-113.	0.9	153
175	Potential use of animal models to examine antipsychotic prophylaxis for schizophrenia. Clinical Neuroscience Research, 2003, 3, 289-296.	0.8	15
176	Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biological Psychiatry, 2003, 53, 352-359.	0.7	116
177	Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biological Psychiatry, 2003, 54, 121-128.	0.7	225
178	Animal behavior models of the mechanisms underlying antipsychotic atypicality. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1071-1079.	2.5	214
179	RO-10-5824 is a selective dopamine D4 receptor agonist that increases novel object exploration in C57 mice. Neuropharmacology, 2003, 44, 473-481.	2.0	82
180	Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology, 2003, 44, 729-737.	2.0	100

#	Article	IF	CITATIONS
181	The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biological Psychology, 2003, 62, 175-195.	1.1	96
182	The acoustic startle reflex and its modulation: effects of age and gender in humans. Biological Psychology, 2003, 63, 311-323.	1.1	92
183	Assessment of Murine Startle Reactivity, Prepulse Inhibition, and Habituation. Current Protocols in Neuroscience, 2003, 24, Unit 8.17.	2.6	78
184	GABA-A and 5-HT1A Receptor Agonists Block Expression of Fear-Potentiated Startle in Mice. Neuropsychopharmacology, 2003, 28, 654-663.	2.8	56
185	Reversal of Startle Gating Deficits in Transgenic Mice Overexpressing Corticotropin-Releasing Factor by Antipsychotic Drugs. Neuropsychopharmacology, 2003, 28, 1790-1798.	2.8	51
186	Dopamine D1 Rather than D2 Receptor Agonists Disrupt Prepulse Inhibition of Startle in Mice. Neuropsychopharmacology, 2003, 28, 108-118.	2.8	100
187	Prestimulus effects on startle magnitude: Sensory or motor?. Behavioral Neuroscience, 2002, 116, 672-681.	0.6	26
188	Neurobiological Measures of Schizotypal Personality Disorder: Defining an Inhibitory Endophenotype?. American Journal of Psychiatry, 2002, 159, 869-871.	4.0	106
189	Reduced startle reactivity and plasticity in transgenic mice overexpressing corticotropin-releasing hormone. Biological Psychiatry, 2002, 51, 583-590.	0.7	76
190	Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophrenia Research, 2002, 55, 129-137.	1.1	103
191	Isolation rearing-induced deficits in prepulse inhibition and locomotor habituation are not potentiated by water deprivation. Physiology and Behavior, 2002, 77, 55-64.	1.0	40
192	Differential Effects of Direct and Indirect Dopamine Agonists on Prepulse Inhibition: A Study in D1 and D2 Receptor Knock-Out Mice. Journal of Neuroscience, 2002, 22, 9604-9611.	1.7	103
193	Subthalamic 5-HT1A and 5-HT1B receptor modulation of RU 24969-induced behavioral profile in rats. Pharmacology Biochemistry and Behavior, 2002, 71, 569-580.	1.3	17
194	"Typical" but not "atypical" antipsychotic effects on startle gating deficits in prepubertal rats. Psychopharmacology, 2002, 161, 38-46.	1.5	19
195	Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacology, 2002, 161, 189-201.	1.5	52
196	Developmental markers of psychiatric disorders as identified by sensorimotor gating. Neurotoxicity Research, 2002, 4, 489-502.	1.3	40
197	Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophrenia Research, 2001, 49, 171-178.	1.1	257
198	Tactile prepuff inhibition of startle in children with Tourette's syndrome: in search of an "fMRI-friendly―startle paradigm. Biological Psychiatry, 2001, 50, 578-585.	0.7	173

#	Article	IF	CITATIONS
199	A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Research Bulletin, 2001, 56, 495-507.	1.4	267
200	5-HT1B receptor knockout, but not 5-HT1A receptor knockout mice, show reduced startle reactivity and footshock-induced sensitization, as measured with the acoustic startle response. Behavioural Brain Research, 2001, 118, 169-178.	1.2	44
201	Post-weaning handling attenuates isolation-rearing induced disruptions of prepulse inhibition in rats. Behavioural Brain Research, 2001, 120, 221-224.	1.2	47
202	Prepulse Inhibition Deficits and Perseverative Motor Patterns in Dopamine Transporter Knock-Out Mice: Differential Effects of D1 and D2 Receptor Antagonists. Journal of Neuroscience, 2001, 21, 305-313.	1.7	248
203	Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology, 2001, 156, 234-258.	1.5	1,562
204	Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology, 2001, 156, 117-154.	1.5	1,404
205	Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin. Neuropsychopharmacology, 2001, 24, 240-252.	2.8	93
206	Prepulse startle deficit in the Brown Norway rat: A potential genetic model Behavioral Neuroscience, 2000, 114, 374-388.	0.6	74
207	"Early―and "Late―Effects of Sustained Haloperidol on Apomorphine- and Phencyclidine-induced Sensorimotor Gating Deficits. Neuropsychopharmacology, 2000, 23, 517-527.	2.8	38
208	Regulation of Sensorimotor Gating of the Startle Reflex by Serotonin 2A Receptors Ontogeny and Strain Differences. Neuropsychopharmacology, 2000, 23, 623-632.	2.8	30
209	Ontogeny of Phencyclidine and Apomorphine-Induced Startle Gating Deficits in Rats. Pharmacology Biochemistry and Behavior, 2000, 65, 449-457.	1.3	40
210	Toward Understanding the Biology of a Complex Phenotype: Rat Strain and Substrain Differences in the Sensorimotor Gating-Disruptive Effects of Dopamine Agonists. Journal of Neuroscience, 2000, 20, 4325-4336.	1.7	163
211	Sensory Gating Deficits Assessed by the P50 Event-Related Potential in Subjects With Schizotypal Personality Disorder. American Journal of Psychiatry, 2000, 157, 55-59.	4.0	197
212	Environmental enrichment and isolation rearing in the rat: effects on locomotor behavior and startle response plasticity. Biological Psychiatry, 2000, 47, 864-873.	0.7	181
213	Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology, 2000, 39, 2170-2179.	2.0	92
214	The genetic liability to stress and postweaning isolation have a competitive influence on behavioral organization in rats. Physiology and Behavior, 2000, 68, 389-394.	1.0	18
215	Prepulse Inhibition as a Cross-Species Model of Sensorimotor Gating Deficits in Schizophrenia. Neurobiological Foundation of Aberrant Behaviors, 2000, , 103-112.	0.2	0
216	The Dopamine D2, but not D3or D4, Receptor Subtype is Essential for the Disruption of Prepulse Inhibition Produced by Amphetamine in Mice. Journal of Neuroscience, 1999, 19, 4627-4633.	1.7	169

#	Article	IF	CITATIONS
217	Dopamine D4 Receptor-Knock-Out Mice Exhibit Reduced Exploration of Novel Stimuli. Journal of Neuroscience, 1999, 19, 9550-9556.	1.7	401
218	Neurophysiology and Neuropharmacology of Short Lead Interval Startle Modification. , 1999, , 114-134.		32
219	Sensorimotor Gating and Thought Disturbance Measured in Close Temporal Proximity in Schizophrenic Patients. Archives of General Psychiatry, 1999, 56, 277.	13.8	236
220	Cross-species Studies of Sensorimotor Gating of the Startle Reflex. Annals of the New York Academy of Sciences, 1999, 877, 202-216.	1.8	160
221	Effects of sustained cocaine exposure on sensorimotor gating of startle in rats. Psychopharmacology, 1999, 142, 253-260.	1.5	33
222	Assessing prepulse inhibition of startle in wild-type and knockout mice. Psychopharmacology, 1999, 147, 11-13.	1.5	37
223	Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains1Published on the World Wide Web on 16 February 1999.1. Brain Research, 1999, 835, 27-36.	1.1	109
224	M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats. Neuropsychopharmacology, 1999, 20, 311-321.	2.8	153
225	Effects of Sustained Phencyclidine Exposure on Sensorimotor Gating of Startle in Rats. Neuropsychopharmacology, 1999, 21, 28-39.	2.8	67
226	The Effects of M100907 in Pharmacological and Developmental Animal Models of Prepulse Inhibition Deficits in Schizophrenia. Neuropsychopharmacology, 1999, 21, S134-S142.	2.8	23
227	Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor. Neuron, 1999, 22, 581-591.	3.8	184
228	Is there a critical developmental `window' for isolation rearing-induced changes in prepulse inhibition of the acoustic startle response?. Behavioural Brain Research, 1999, 100, 177-183.	1.2	67
229	Ontogeny of Isolation Rearing-Induced Deficits in Sensorimotor Gating in Rats. Physiology and Behavior, 1999, 67, 385-392.	1.0	105
230	Prepulse inhibition and habituation of the startle response are stable neurobiological measures in a normal male population. Biological Psychiatry, 1999, 45, 360-364.	0.7	96
231	Amphetamine disrupts P50 suppression in normal subjects. Biological Psychiatry, 1999, 46, 990-996.	0.7	102
232	Effects of discrete acoustic prestimuli on perceived intensity and behavioral responses to startling acoustic and tactile stimuli. Cognitive, Affective and Behavioral Neuroscience, 1999, 27, 547-556.	1.2	34
233	Effects of Hallucinogens on Locomotor and Investigatory Activity and Patterns: Influence of 5-HT2A and 5-HT2C Receptors. Neuropsychopharmacology, 1998, 18, 339-351.	2.8	70
234	Discrepant Findings of Clozapine Effects on Prepulse Inhibition of Startle: Is It the Route or the Rat?. Neuropsychopharmacology, 1998, 18, 50-56.	2.8	86

#	Article	IF	CITATIONS
235	Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacology, 1998, 140, 75-80.	1.5	122
236	Isolation rearing affects sequential organization of motor behavior in post-pubertal but not pre-pubertal Lister and Sprague–Dawley rats. Behavioural Brain Research, 1998, 94, 271-280.	1.2	57
237	Measurement of Startle Response, Prepulse Inhibition, and Habituation. Current Protocols in Neuroscience, 1998, 3, 8.7.1-8.7.15.	2.6	136
238	Disruption in prepulse inhibition after alpha-1 adrenoceptor stimulation in rats. Neuropharmacology, 1998, 37, 401-404.	2.0	65
239	Differential Movement Patterns But Not Amount of Activity in Unconditioned Motor Behavior of Fischer, Lewis, and Sprague–Dawley Rats. Physiology and Behavior, 1998, 65, 601-606.	1.0	20
240	Reversal of Isolation Rearing-Induced Deficits in Prepulse Inhibition by Seroquel and Olanzapine. Biological Psychiatry, 1998, 43, 436-445.	0.7	131
241	Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. European Journal of Pharmacology, 1998, 343, 135-143.	1.7	28
242	Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schizophrenia Research, 1998, 30, 71-80.	1.1	109
243	Poor P50 Suppression Among Schizophrenia Patients and Their First-Degree Biological Relatives. American Journal of Psychiatry, 1998, 155, 1691-1694.	4.0	281
244	Effects of isolation rearing on startle reactivity, habituation, and prepulse inhibition in male Lewis, Sprague-Dawley, and Fischer F344 rats Behavioral Neuroscience, 1998, 112, 1450-1457.	0.6	99
245	Multiple Limbic Regions Mediate the Disruption of Prepulse Inhibition Produced in Rats by the Noncompetitive NMDA Antagonist Dizocilpine. Journal of Neuroscience, 1998, 18, 8394-8401.	1.7	165
246	P50 Suppression among schizophrenia and normal comparison subjects: A methodological analysis. Biological Psychiatry, 1997, 41, 1035-1044.	0.7	165
247	Characterization of the Disruptions of Prepulse Inhibition and Habituation of Startle Induced by α-Ethyltryptamine. Neuropsychopharmacology, 1997, 16, 246-255.	2.8	51
248	DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Research, 1997, 761, 97-104.	1.1	112
249	Environment and unconditioned motor behavior: Influences of drugs and environmental geometry on behavioral organization in rats. Cognitive, Affective and Behavioral Neuroscience, 1997, 25, 327-337.	1.2	17
250	Latent inhibition in schizophrenia. Schizophrenia Research, 1996, 20, 91-103.	1.1	185
251	8-OH-DPAT disruption of prepulse inhibition in rats: reversal with (+)WAY 100,135 and localization of site of action. Psychopharmacology, 1995, 117, 41-48.	1.5	90
252	Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology, 1995, 122, 198-201.	1.5	178

#	Article	IF	CITATIONS
253	Effects of D3/D2 Dopamine Receptor Agonists and Antagonists on Prepulse Inhibition of Acoustic Startle in the Rat. Neuropsychopharmacology, 1995, 12, 139-145.	2.8	70
254	Serotonergic functions in arousal and motor activity. Behavioural Brain Research, 1995, 73, 31-35.	1.2	141
255	"Normal―personality correlates of sensorimotor, cognitive, and visuospatial gating. Biological Psychiatry, 1995, 37, 286-299.	0.7	141
256	Drug screening in "normal―controls. Biological Psychiatry, 1995, 38, 123-124.	0.7	11
257	Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology, 1994, 113, 429-437.	1.5	26
258	Flinders resistant hypocholinergic rats exhibit startle sensitization and reduced startle thresholds. Biological Psychiatry, 1994, 36, 680-688.	0.7	20
259	Social Isolation in the Rat Produces Developmentally Specific Deficits in Prepulse Inhibition of the Acoustic Startle Response Without Disrupting Latent Inhibition. Neuropsychopharmacology, 1994, 10, 61-72.	2.8	253
260	Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacology Biochemistry and Behavior, 1993, 44, 741-744.	1.3	183
261	Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology, 1993, 111, 169-178.	1.5	20
262	Quantitative assessment of the microstructure of rat behavior: I.f(d), The extension of the scaling hypothesis. Psychopharmacology, 1993, 113, 177-186.	1.5	26
263	Quantitative assessment of the microstructure of rat behavior: II. Distinctive effects of dopamine releasers and uptake inhibitors. Psychopharmacology, 1993, 113, 187-198.	1.5	28
264	Men are more inhibited than women by weak prepulses. Biological Psychiatry, 1993, 34, 253-260.	0.7	209
265	Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biological Psychiatry, 1993, 34, 361-372.	0.7	362
266	Three independent factors characterize spontaneous rat motor activity. Behavioural Brain Research, 1993, 53, 11-20.	1.2	67
267	Serotonin1B Receptor Activation Mimics Behavioral Effects of Presynaptic Serotonin Release. Neuropsychopharmacology, 1993, 8, 201-211.	2.8	89
268	Differential Startle Amplitude and Corticosterone Response in Rats. Neuroendocrinology, 1992, 56, 719-723.	1.2	81
269	Responding to acoustic startle during chronic ethanol intoxication and withdrawal. Psychopharmacology, 1992, 106, 351-358.	1.5	101
270	A scaling approach to find order parameters quantifying the effects of dopaminergic agents on unconditioned motor activity in rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1991, 15, 903-919.	2.5	43

#	Article	IF	CITATIONS
271	Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biological Psychiatry, 1991, 30, 557-566.	0.7	185
272	Opiate-dopamine interactions in the neural substrates of acoustics startle gating in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1991, 15, 415-426.	2.5	34
273	Statistical mechanics of a neurobiological dynamical system: The spectrum of local entropies (S(α)) applied to cocaine-perturbed behavior. Physica A: Statistical Mechanics and Its Applications, 1991, 174, 567-577.	1.2	8
274	Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology, 1991, 105, 69-76.	1.5	48
275	Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology, 1991, 105, 162-168.	1.5	128
276	A temporal and spatial scaling hypothesis for the behavioral effects of psychostimulants. Psychopharmacology, 1991, 104, 6-16.	1.5	121
277	Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology, 1991, 104, 293-301.	1.5	67
278	Multiple serotonergic influences on startle responding. Journal of Psychopharmacology, 1991, 5, 334-335.	2.0	1
279	5HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacology, 1990, 100, 417-425.	1.5	84
280	Apomorphine disrupts the inhibition of acoustic startle induced by weak prepulses in rats. Psychopharmacology, 1990, 102, 1-4.	1.5	138
281	Direct Cerebrospinal Fluid Delivery of an Antiretroviral Agent Using Multivesicular Liposomes. Journal of Infectious Diseases, 1990, 162, 750-752.	1.9	55
282	Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Research Bulletin, 1990, 25, 485-498.	1.4	440
283	Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology, 1989, 98, 321-329.	1.5	58
284	Prepulse inhibition of the acoustic startle response is disrupted by N-ethyl-3,4-methylenedioxyamphetamine (MDEA) in the rat. European Journal of Pharmacology, 1989, 167, 49-55.	1.7	63
285	Increases in diversive exploration in rats during hippocampal microinfusions of isoproterenol but not methoxamine. Physiology and Behavior, 1989, 45, 213-217.	1.0	8
286	Failure of haloperidol to block the disruption of sensory gating induced by phencyclidine and MK801. Biological Psychiatry, 1989, 25, A169-A170.	0.7	10
287	Peripheral mediation of effects of clenbuterol on locomotor and investigatory behavior in rats. Pharmacology Biochemistry and Behavior, 1988, 30, 417-420.	1.3	15
288	Dopaminergic stimulation disrupts sensorimotor gating in the rat. Psychopharmacology, 1988, 94, 507-514.	1.5	576

#	Article	IF	CITATIONS
289	Gabaergic interneurons in the dorsal raphe mediate the effects of apomorphine on serotonergic system. Brain Research Bulletin, 1987, 18, 345-353.	1.4	25
290	Sequential changes in behavior induced by continuous infusions of amphetamine in rats. Psychopharmacology, 1987, 91, 217-20.	1.5	7
291	Effects of apomorphine and amphetamine on patterns of locomotor and investigatory behavior in rats. Pharmacology Biochemistry and Behavior, 1987, 28, 393-399.	1.3	156
292	The behavioral effects of depletions of brain serotonin induced by 5,7-dihydroxytryptamine vary with time after administration. Behavioral and Neural Biology, 1986, 45, 31-42.	2.3	25
293	The role of serotonin in behavior: An unfulfilled promise. Behavioral and Brain Sciences, 1986, 9, 338-339.	0.4	2
294	Multivariate assessment of locomotor behavior: Pharmacological and behavioral analyses. Pharmacology Biochemistry and Behavior, 1986, 25, 277-288.	1.3	201
295	A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats Behavioral Neuroscience, 1985, 99, 881-900.	0.6	54
296	Depletion of brain serotonin by 5,7-dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats. Psychopharmacology, 1985, 87, 400-405.	1.5	50
297	Patterns of exploration in rats distinguish lisuride from lysergic acid diethylamide. Pharmacology Biochemistry and Behavior, 1985, 23, 461-468.	1.3	23
298	Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1985, 9, 121-132.	2.5	31
299	Effects of clonidine, piperoxane and locus coeruleus lesion on the serotonergic and dopaminergic systems in raphe and caudate nucleus. Biochemical Pharmacology, 1984, 33, 3399-3404.	2.0	32
300	Behavior during hippocampal microinfusions. I. Norepinephrine and diversive exploration. Brain Research Reviews, 1982, 4, 79-103.	9.1	94
301	Effects of tactile startle on serotonin content of midbrain raphe neurons in rats. Behavioural Brain Research, 1982, 4, 369-376.	1.2	10
302	Selective effects of apomorphine on dorsal raphe neurons: A cytofluorimetric study. Brain Research Bulletin, 1982, 9, 719-725.	1.4	30
303	LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology, 1982, 77, 179-185.	1.5	56
304	Habituation of the Blink Reflex in Normals and Schizophrenic Patients. Psychophysiology, 1982, 19, 1-6.	1.2	199
305	Effects of Levonantradol on Habituation of Startle in Rats. Journal of Clinical Pharmacology, 1981, 21, 235S-239S.	1.0	6
306	Effects of 6-hydroxydopamine lesions of locus coeruleus on startle in rats. Psychopharmacology, 1981, 73, 394-398.	1.5	62

#	Article	IF	CITATIONS
307	Decreased startle reactivity in the end-to-side portacaval shunted rat. Pharmacology Biochemistry and Behavior, 1980, 12, 739-742.	1.3	21
308	Both indoleamine and phenylethylamine hallucinogens increase serotonin in both dorsal and median raphe neurons. Life Sciences, 1980, 26, 431-434.	2.0	5
309	Effects of serotonergic lesions on investigatory responding by rats in a holeboard. Behavioral and Neural Biology, 1980, 30, 160-177.	2.3	55
310	A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology, 1979, 65, 35-40.	1.5	51
311	LSD-induced alterations of investigatory responding in rats. Psychopharmacology, 1979, 65, 41-47.	1.5	18
312	Mescaline increases startle responding equally in normal and raphe-lesioned rats. Pharmacology Biochemistry and Behavior, 1979, 10, 293-298.	1.3	6
313	LITHIUM DECREASES AND COCAINE INCREASES THE BILATERAL ASYMMETRY OF SEROTONIN IN MESOSTRIATAL AND MESOLIMBIC SYSTEMS ASSOCIATED WITH CHANGES IN THE KINETIC PROPERTIES OF TRYPTOPHAN HYDROXYLASE. , 1979, , 663-665.		3
314	SIMILAR EFFECTS OF INDOLEAMINE AND PHENYLETHYLAMINE HALLUCINOGENS ON DORSAL AND MEDIAN RAPHE NEURONS. , 1979, , 1304-1306.		1
315	EUPHOROHALLUCINOGENS - TOWARD A BEHAVIORAL MODEL. , 1978, , 310-323.		0
316	Histologic and enzymatic studies of the mesolimbic and mesostriatal serotonergic pathways. Brain Research, 1976, 106, 241-256.	1.1	221
317	Behavioral studies following lesions of the mesolimbic and mesostriatal serotonergic pathways. Brain Research, 1976, 106, 257-270.	1.1	301
318	Opposite effects of intraventricular serotonin and bufotenin on rat startle responses. Pharmacology Biochemistry and Behavior, 1975, 3, 687-691.	1.3	34
319	Differential effects of caffeine, D-amphetamine and methylphenidate on individual raphe cell fluorescence: a microspectrofluorimetric demonstration. Brain Research, 1975, 85, 135-139.	1.1	35
320	Differential effects of reserpine and alpha-methyl-p-tyrosine on norepinephrine and dopamine induced behavioral activity. Psychopharmacology, 1973, 29, 131-140.	1.5	56
321	Regional Distribution of 5-Methyltetrahydrofolic Acid in Brain. Nature: New Biology, 1973, 245, 244-245.	4.5	36
322	Effect of intraventricular infusion of dopamine and norepinephrine on motor activity. Physiology and Behavior, 1972, 8, 653-658.	1.0	92